Cervomed publishes positive results from ascend-lb phase 2a trial in peer-reviewed journal that supports the therapeutic potential of neflamapimod in dementia with lewy bodies

-integrated summary of all previously published phase 2a clinical results, together with the first peer reviewed publication of eeg and mri results, substantially derisk the ongoing rewind-lb phase 2b trial of neflamapimod in dementia with lewy bodies -
CRVO Ratings Summary
CRVO Quant Ranking